Merus News

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage...

PR Newswire11:50

Merus (MRUS) Initiated With a Buy at Truist Financial

TipRanksMay 14 09:05

Bank of America Securities Remains a Buy on Merus (MRUS)

TipRanksMay 13 08:37

Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation

By Dean Seal Merus said federal regulators have granted breakthrough therapy designation to its carcinoma treatment petosemtamab. The clinical-stage oncology company said Monday that the Food and Dr

WSJMay 13 07:38

Petosemtamab Receives Breakthrough Therapy Designation From FDA

Merus N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic hea

BenzingaMay 13 07:23

FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

BenzingaMay 13 07:21

Buy Rating on Merus Stock Amid Anticipation of Positive Clinical Trial Results and Growing Investor Interest

TipRanksMay 13 05:56

Needham: Reiterates Merus (MRUS.US) rating and adjusted from buy to buy rating, target price is $66.00.

Needham: Reiterates Merus (MRUS.US) rating and adjusted from buy to buy rating, target price is $66.00.

Zhitong FinanceMay 13 05:50

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Merus (NASDAQ:MRUS) stock is up 116% in the last year, providing strong gains for shareholders.

Simply Wall StMay 10 07:45

HC Wainwright & Co. Reiterates Buy on Merus, Maintains $65 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $65 price target.

BenzingaMay 9 06:28

Buy Rating Affirmed for Merus on Promising HNSCC Clinical Data and Competitive Outlook

TipRanksMay 9 05:36

Merus Q1 EPS $(0.59) Beats $(0.81) Estimate, Sales $7.89M Miss $9.74M Estimate

Merus (NASDAQ:MRUS) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.81) by 27.16 percent. This is a 31.4 percent increase over losses of $(0.86) per sha

BenzingaMay 8 17:35

Earnings Flash (MRUS) MERUS N.V. Posts Q1 Revenue $7.9M

04:27 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (MRUS) MERUS N.V. Posts Q1 Revenue $7.9M

MT NewswiresMay 8 15:27

Press Release: Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update -- Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024

Dow JonesMay 8 15:15

Merus 1Q Loss/Shr 59c >MRUS

Merus 1Q Loss/Shr 59c >MRUS

Dow JonesMay 8 15:15

Merus | 10-Q: Quarterly report

Futu NewsMay 8 15:11 · Announcements

Merus NV Shareholders Endorse Governance and Incentive Plans

TipRanksMay 8 07:12

FDA Accepts Merus Application for Zeno for Lung, Pancreatic Cancer

Seeking AlphaMay 6 15:45

Merus Announces U.S. FDA Acceptance And Priority Review Of BLA For Zeno For The Treatment Of NRG1+ NSCLC And PDAC

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced tha

BenzingaMay 6 15:28

On April 30, Cinda Biopharmaceuticals announced the appointment of Samuel Zhang (Samuel Zhang) as the Global Chief Commercial Officer (CBO). Zhang Suhua will report to Yu Dechao, the founder, chairman and CEO of the company, who is responsible for the str

On April 30, Cinda Biopharmaceuticals announced the appointment of Samuel Zhang (Samuel Zhang) as the Global Chief Commercial Officer (CBO). Zhang Suhua will report to Yu Dechao, the founder, chairman and CEO of the company, who is responsible for the strategic planning and business development of Cinda Biotech's global business. Prior to joining Cinda Biotech, Zhang Suhua was the chief commercial officer of Genxi Biotech and NeoImmune Tech, leading the $1.2 billion acquisition partnership between Genxi Biotech and AstraZeneca. He has also held various management positions at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus.

Zhitong FinanceApr 29 23:55